Reimer P, Weissleder R, Lee A S, Buettner S, Wittenberg J, Brady T J
Department of Radiology, Massachusetts General Hospital, Charlestown.
Radiology. 1991 Mar;178(3):769-74. doi: 10.1148/radiology.178.3.1994416.
An arabinogalactan-coated ultrasmall superparamagnetic iron oxide (AG-USPIO) preparation specific for asialoglycoprotein (ASG) receptors on hepatocytes was used as a magnetic resonance (MR) imaging contrast agent in the evaluation of a spectrum of benign liver diseases in animal models. The activity of hepatocyte ASG receptors, which directly reflects liver function, was directly assessed by measuring liver relaxation times in vitro and MR signal intensity in vivo. The following measurements allowed three-dimensional assessment of liver function: (a) liver relaxation time, (b) native MR signal intensities of liver, (c) response of liver to the AG-USPIO probe (percentage decrease of liver signal intensity after intravenous administration of 10 mumol/kg of AG-USPIO: normal liver 55%, fatty liver 57%, acute hepatitis 36%, chronic hepatitis 29%, and cirrhosis 46%), and (d) redistribution of hepatocyte-specific AG-USPIO to the spleen (present in hepatitis and cirrhosis but not in normal liver and fatty liver). The results of this study indicate that cellular hepatic abnormalities can be detected and quantitated with MR receptor imaging.
一种特异性针对肝细胞上去唾液酸糖蛋白(ASG)受体的阿拉伯半乳聚糖包被的超小超顺磁性氧化铁(AG-USPIO)制剂被用作磁共振(MR)成像造影剂,用于评估动物模型中的一系列良性肝脏疾病。通过体外测量肝脏弛豫时间和体内MR信号强度,直接评估了直接反映肝功能的肝细胞ASG受体活性。以下测量可对肝功能进行三维评估:(a)肝脏弛豫时间,(b)肝脏的原始MR信号强度,(c)肝脏对AG-USPIO探针的反应(静脉注射10 μmol/kg的AG-USPIO后肝脏信号强度的降低百分比:正常肝脏为55%,脂肪肝为57%,急性肝炎为36%,慢性肝炎为29%,肝硬化为46%),以及(d)肝细胞特异性AG-USPIO向脾脏的重新分布(存在于肝炎和肝硬化中,但不存在于正常肝脏和脂肪肝中)。这项研究的结果表明,通过MR受体成像可以检测和定量肝脏细胞异常情况。